Location：Home/News/Company NewsOn February 13, 2023, Beijing time, the National Medical Products Administration (NMPA) accepted the
KeChow Pharma’s independently developed MEK inhibitor, Tunlametinib (HL-085), in combination with Ve
KeChow Pharma’s chemoprotective agent, HL-003, has received clinical approval from the National Medi
December 3, 2022, Shanghai - Today marked the online convening of the 2022 China Healthcare Summit o
On July 5, 2022, KeChow Pharma submitted an application for a pre-marketing communication meeting fo
KeChow Pharma announced that its MEK inhibitor, HL-085, for treating advanced NRAS-mutant melanoma,
